On April 21, 2026 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, reported they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place on May 29-June 2 in Chicago, Illinois. The presentation will include detail and additional data from OptimUM-02 that were not disclosed with the company’s topline release.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details
Late-Breaking Abstract Number: LBA9503
Date and Time: June 1, 2026, 8-11AM CDT, Oral Abstract Session, Melanoma/Skin Cancers
Title: Darovasertib Plus Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 trial
Presenter: Dr. Marlana Orloff, M.D., Associate Professor of Medical Oncology, Thomas Jefferson University Hospital
(Press release, Ideaya Biosciences, APR 21, 2026, View Source [SID1234664637])